Edition:
United States

Alliqua BioMedical Inc (ALQA.OQ)

ALQA.OQ on NASDAQ Stock Exchange Capital Market

2.20USD
4:00pm EDT
Change (% chg)

$-0.18 (-7.56%)
Prev Close
$2.38
Open
$2.26
Day's High
$2.30
Day's Low
$2.17
Volume
2,227
Avg. Vol
3,310
52-wk High
$4.55
52-wk Low
$1.59

Latest Key Developments (Source: Significant Developments)

Alliqua Biomedical Says Has Right To Terminate Agreement With Celularity, Provided Co Pays $1.45 Mln Fee
Friday, 5 Jan 2018 05:22pm EST 

Jan 5 (Reuters) - Alliqua Biomedical Inc ::ALLIQUA BIOMEDICAL SAYS HAS RIGHT TO TERMINATE ASSET PURCHASE AGREEMENT WITH CELULARITY, PROVIDED CO PAYS TERMINATION FEE OF $1.45 MILLION - SEC FILING.ALLIQUA BIOMEDICAL INC - CELULARITY MAY BE OBLIGATED TO PAY A $3 MILLION REVERSE TERMINATION FEE IF ASSET PURCHASE AGREEMENT IS TERMINATED BY CO.  Full Article

Alliqua Biomedical Announces Definitive Asset Purchase Agreement With Celularity Inc
Friday, 5 Jan 2018 04:30pm EST 

Jan 5 (Reuters) - Alliqua Biomedical Inc ::ALLIQUA BIOMEDICAL, INC. ANNOUNCES DEFINITIVE ASSET PURCHASE AGREEMENT WITH CELULARITY, INC..ALLIQUA BIOMEDICAL INC - DEAL FOR $29.0 MILLION.ALLIQUA BIOMEDICAL - AS PER DEAL, CELULARITY WILL ACQUIRE ALL OF PROPERTY, ASSETS AND RIGHTS RELATING TO CO'S ADVANCED BIOLOGIC WOUND CARE BUSINESS.ALLIQUA BIOMEDICAL - AS PER DEAL, CELULARITY WILL ALSO ACQUIRE ALL OF PROPERTY, ASSETS AND RIGHTS RELATING TO CO'S ULTRAMIST THERAPY SYSTEM.ALLIQUA BIOMEDICAL INC - CO'S BOARD OF DIRECTORS UNANIMOUSLY APPROVED ENTERING INTO AGREEMENT.ALLIQUA BIOMEDICAL INC - NO DEBT OR SIGNIFICANT LIABILITIES ARE BEING ASSUMED BY CELULARITY IN TRANSACTION.  Full Article

Alliqua BioMedical engages Cowen to assist in evaluating potential strategic alternatives
Thursday, 9 Nov 2017 07:01am EST 

Nov 9 (Reuters) - Alliqua BioMedical Inc :Alliqua BioMedical Inc engages Cowen to assist in evaluating potential strategic alternatives.Alliqua BioMedical Inc - engaged Cowen as its independent financial advisor to assist co in evaluating potential strategic alternatives​.  Full Article

Alliqua Biomedical announces 1-for-10 reverse stock split
Thursday, 5 Oct 2017 04:01pm EDT 

Oct 5 (Reuters) - Alliqua Biomedical Inc :Alliqua Biomedical Inc announces 1-for-10 reverse stock split.Company's common stock will begin trading on split-adjusted basis on Friday, October 6, 2017.  Full Article

Alliqua Biomedical sells TheraBond 3D Antimicrobial Barrier Systems product line
Tuesday, 5 Sep 2017 07:30am EDT 

Sept 5 (Reuters) - Alliqua Biomedical Inc :Alliqua Biomedical Inc announces the sale of TheraBond 3D Antimicrobial Barrier Systems product line; Alliqua updates fiscal year outlook.Sees FY 2017 revenue up about 13 to 19 percent.Sees FY 2017 revenue $18.4 million to $19.3 million.Alliqua Biomedical Inc - for fiscal year 2017 company still expects cash burn from operations to be approximately $12.0 million.Alliqua Biomedical says Alliqua sold all assets associated with its TheraBond 3D Antimicrobial Barrier Systems product line to Argentum Medical, LLC.Alliqua Biomedical Inc - Alliqua will use proceeds from sale for working capital purposes and to reduce its outstanding debt balance.Alliqua Biomedical Inc - as a result of the transaction, company's lender has agreed to defer all principal payments until January 31, 2018.Alliqua Biomedical Inc - aggregate purchase price for TheraBond product line was approximately $3.8 million.Alliqua Biomedical - net of payments to Alliqua's senior secured lender of $1.65 million, Alliqua received proceeds of approximately $1.65 million at closing.  Full Article

Alliqua Biomedical posts Q2 adj. $0.09/shr from continuing operations
Thursday, 10 Aug 2017 07:00am EDT 

Aug 10 (Reuters) - Alliqua Biomedical Inc :Alliqua Biomedical Inc reports second quarter of fiscal year 2017 financial results.Q2 non-GAAP loss per share $0.09 from continuing operations.Q2 GAAP loss per share $0.09.Q2 revenue rose 24 percent to $5.5 million.Sees FY 2017 revenue up about 12 to 17 percent.Sees FY 2017 revenue $20.4 million to $21.3 million.  Full Article

Alliqua announces partnership with Partners Capital Group
Monday, 19 Jun 2017 07:30am EDT 

June 19 (Reuters) - Alliqua Biomedical Inc ::Alliqua Biomedical Inc announces partnership with Partners Capital Group to provide Ultramist® customers with new equipment financing programs.Alliqua Biomedical - entered into partnership with Partners Capital Group to provide potential Ultramist customers with new equipment financing programs.  Full Article

Alliqua Biomedical reports Q1 loss per share of $0.23
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Alliqua Biomedical Inc :Alliqua biomedical, inc. Reports first quarter of fiscal year 2017 financial results.Q1 non-GAAP loss per share $0.17 from continuing operations.Q1 GAAP loss per share $0.23.Q1 revenue $4.6 million versus I/B/E/S view $4.4 million.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue up about 12 to 17 percent.Sees FY 2017 revenue $20.4 million to $21.3 million.FY2017 revenue view $20.3 million -- Thomson Reuters I/B/E/S.For fiscal year 2017, company expects cash burn from operations to approximate $12.0 million.  Full Article

Alliqua Biomedical says Company, unit and perceptive entered into amendment No.2 to forbearance and amendment agreement
Monday, 1 May 2017 09:31am EDT 

May 1 (Reuters) - Alliqua Biomedical Inc :Alliqua biomedical - on april 27, 2017, company, unit and perceptive entered into amendment no.2 to forbearance and amendment agreement - sec filing.Alliqua biomedical inc - pursuant to amedment perceptive agreed to extend forbearance period until earlier of june 30, 2017.  Full Article

Alliqua Biomedical says co, Perceptive enters amendment to reduce exercise price
Wednesday, 12 Apr 2017 01:34pm EDT 

Alliqua Biomedical Inc :On April 6, co, Perceptive entered amendment, restatement of third amended warrant to reduce exercise price from $0.50 to $0.47.  Full Article

BRIEF-Alliqua Biomedical Terminates Credit Agreement & Guaranty Dated May 29, 2015

* ALLIQUA BIOMEDICAL SAYS ON MAY 7,IN RELATION TO COMPLETION OF ASSET SALE, CO TERMINATED CREDIT AGREEMENT & GUARANTY DATED MAY 29, 2015 - SEC FILING